

STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL

USAN (JK-140) PIMIVALIMAB
 PRONUNCIATION pim" i val' i mab
 THERAPEUTIC CLAIM Treatment of cancer

CHEMICAL NAMES

1. Immunoglobulin G4 [226-proline,C-terminal-lysine-clipped], anti-(human programmed cell death protein 1) (human monoclonal JTX-4014 γ 4-chain), disulfide with human monoclonal JTX-4014 κ -chain, dimer (Source: CAS)
2. Immunoglobulin G4-kappa, anti-[*Homo sapiens* Programmed cell death 1 ligand 1 (PD-L1; CD274 antigen)]; human monoclonal antibody; γ 4 heavy chain *Homo sapiens* (1-444) [VH *Homo sapiens* (IGHV1-46*01 (97%) – (IGHD)-IGHJ5*02) [8.8.11] (1-118) -*Homo sapiens* IGHG4*01 {[hinge[S¹⁰>P(226)], CH3[K¹⁰⁷>del(445)]} (119-444)] (132-214')-disulfide with κ light chain *Homo sapiens* (1'-214') [V-KAPPA (*Homo sapiens* IGKV1-5*01 (98%) –IGKJ4*01)[6.3.9] (1'-107') -*Homo sapiens* IGKC*01 (108'-214')], dimer (224-224':227-227'')-bisdisulfide, produced in CHO cell, glycoform alfa (Source: USAN Program chemical consultant)

STRUCTURAL FORMULA

Heavy chain X & X''

| | | | | | |
|------------|-------------|------------|------------|------------|-----|
| QVQLVQSGAE | VKPKGASVKV | SCKASGYTFP | SYMHWVRQA | PGQGLEWMGI | 50 |
| INPEGGSTAY | AQKFQGRVTM | TRDTSTSTVY | MELSSLRSED | TAVYYCARGG | 100 |
| TYDYTYWGQ | GTLVTVSSAS | TKGPSVFPLA | PCSRSTSEST | AALGCLVKDY | 150 |
| FPEPVTVSWN | SGALTSGVHT | FPAVLQSSGL | YLSLSSVTVP | SSSLGTKTYT | 200 |
| CNVDHKPSNT | KVDKRVESKY | GPCCPPCPAP | EFLGGPSVFL | FPPKPKDTLM | 250 |
| ISRTPEVTCV | VVDVDSQEDPE | VQFNWYVDGV | EVHNAKTKPR | EEQFNSTYRV | 300 |
| VSVLTVLHQD | WLNKKEYKCK | VSNKGLPSSI | EKTISKAKGQ | PREPQVYTLF | 350 |
| PSQEEMTKNQ | VSLTCLVKGF | YPSDIAVEWE | SNGQPENNYK | TTPPVLDSDG | 400 |
| SFFLYSRLTV | DKSRWQEGNV | FSCSVMHEAL | HNHYTQKSLS | LSLG | 444 |

Light chain X' & X'''

| | | | | | |
|------------|------------|------------|-------------|------------|------|
| DIQMTQSPST | LSASVGDRVT | ITCRASQGIS | SWLAWYQQKP | GKAPKLLIYE | 50' |
| ASSLESGVPS | RFSGSGSGTE | FTLTISSLQP | DDFATYYCQQ | YNSFPPTFGG | 100' |
| GTKVEIKRTV | AAPSVFIFPP | SDEQLKSGTA | SVVCLLNNFY | PREAKVQWKV | 150' |
| DNALQSGNSQ | ESVTEQDSKD | STYLSSTLT | LSKADYEEKHK | VYACEVTHQG | 200' |
| LSSPVTKSFN | RGEC | | | | 214' |

Disulfide bridges location

| | | | | | | | |
|---------|-------------|-----------|-------------|----------|-------------|-----------|---------------|
| 22-96 | 22''-96'' | 23'-88' | 23'''-88''' | 132-214' | 132''-214'' | 134'-194' | 134'''-194''' |
| 145-201 | 145''-201'' | 224-224'' | 227-227'' | 259-319 | 259''-319'' | 365-423 | 365''-423'' |

Glycosylation sites (N)

Asn-295 Asn-295''

MOLECULAR FORMULA

C₆₄₀₀H₉₈₄₄N₁₆₈₄O₂₀₂₀S₄₈ including K(445 &445'') deleted

MOLECULAR WEIGHT

144.24 kDa including K(445 &445'') deleted

| | |
|----------------------------|---------------------------|
| TRADEMARK | None as yet |
| SPONSOR | Jounce Therapeutics, Inc. |
| CODE DESIGNATIONS | JTX-4014 |
| <u>CAS</u> REGISTRY NUMBER | 2293951-22-9 |
| UNII | MA05AF40UO |
| WHO NUMBER | 11461 |

gbk